J. Wolchok

Oncology · 2009–2023

A researcher in the Science corpus: 66 papers; trusts 22 researchers and is trusted by 35 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 888 citations into it; #51 of 1,698 by trust here, #1 by citations
• Immunology — 698 citations into it; #595 of 2,160 by trust here, #4 by citations
• Molecular Biology — 367 citations into it; #10,431 of 17,773 by trust here, #146 by citations

Whom J. Wolchok trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. C. Robert
2. F. Hodi
3. W. Zou
4. M. Postow
5. D. Pardoll
6. S. Topalian
7. Antoni Ribas
8. Lieping Chen
9. Janis Taube
10. Ton N. Schumacher

Who trusts J. Wolchok overall

1. M. Postow
2. Anand Rotte
3. C. Robert
4. Padmanee Sharma
5. S. Topalian
6. J. Haanen
7. Antoni Ribas
8. M. Callahan
9. S. Patel
10. F. Hodi

Papers from J. Wolchok's perspective

Ordered by how strongly the researchers J. Wolchok trusts endorse each paper. Same corpus, a different order for every researcher.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
2. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
3. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
4. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
5. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (Nature Medicine)
6. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
7. Cancer immunoediting: from immunosurveillance to tumor escape (Nature Immunology)
8. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
9. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
10. An immune-active tumor microenvironment favors clinical response to ipilimumab (Cancer Immunology and Immunotherapy)

Their papers

• Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET (2012) — 3,522 citations
• KIT as a therapeutic target in metastatic melanoma. (2011) — 806 citations
• Genetic basis for clinical response to CTLA-4 blockade in melanoma. (2014) — 3,876 citations
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. (2014) — 1,629 citations
• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (2010) — 14,544 citations
• Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma (2015) — 4,132 citations
• Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses (2016) — 684 citations
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. (2011) — 4,405 citations
• Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (2015) — 2,625 citations
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (2015) — 4,195 citations
• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial (2015) — 1,509 citations
• Identification of unique neoantigen qualities in long term pancreatic cancer survivors. (2017) — 1,016 citations
• Hepatotoxicity with combination of vemurafenib and ipilimumab. (2013) — 697 citations
• Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. (2016) — 1,024 citations
• Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis (2016) — 915 citations
• Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. (2015) — 926 citations
• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (2017) — 3,400 citations
• Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. (2017) — 985 citations
• Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy (2016) — 1,211 citations
• Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. (2015) — 1,127 citations